Schlemm's canal surgery with the Stegmann canal expander: two years results

Session Details

Session Title: Glaucoma I

Session Date/Time: Monday 07/09/2015 | 08:00-10:30

Paper Time: 09:30

Venue: Room 10

First Author: : M.Grieshaber SWITZERLAND

Co Author(s): :    A. Schoetzau   H. Grieshaber   R. Stegmann              

Abstract Details

Purpose:

To investigate safety and efficacy of canaloplasty using the Stegmann Canal expander in Europeans with primary open-angle glaucoma (POAG).

Setting:

Prospective, non-comparative study of thirty-four eyes of 34 consecutive patients with medically uncontrolled POAG underwent primary canaloplasty and implantation of the Stegmann Canal Expander into Schlemm's canal with a follow-up time of at least two years. University Hospital Basel, Switzerland

Methods:

Schlemm's canal was unroofed ab externo, and dilated with viscoelastic material and microcatheter. The Stegmann Canal Expander was implanted into the canal lumen, and the superficial scleral flap was closed watertight. Laser goniopuncture of the trabeculo-Descemet's membrane window was performed if postoperative intraocular pressure (IOP) exceeded 16 mm Hg.

Results:

The mean IOP dropped from 26.6 ± 4.2 mm Hg preoperatively to 12.1 ± 2.6 mm Hg at 1 month, 13.1± 1.9 mmHg at 6 months, 13.0 ± 1.9 mm Hg at 12 months, and 13.4 ± 2.4 mm Hg at 24 months (p less than 0.001). Laser goniopuncture was performed on 5 eyes (14.7%) 6.4 months after surgery; the mean IOP was 19.1 mm Hg before and 14.1 mm Hg after goniopuncture. The number of medications dropped from 2.9 ± 0.3 before surgery to 0.1 ± 0.3 after surgery (p less than 0.001). Complications were minor and included microhyphema (14 eyes) and transient elevated IOP (steroid responder; 4 eyes), partial peripheral Descemet's membrane detachment (2 eyes).

Conclusions:

Canaloplasty and implantation of the Stegmann Canal Expander lowered IOP markedly and safely in POAG in this two-year study period.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented